Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-8736 in healthy adult subjects
NCT07141199Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABBV-8736 (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events at 113 days, Maximum Observed Concentration of ABBV-8736 at 113 days and 7 more. Started Sep 2025; status: completed.
02
Drugs
ABBV-8736
Beyond the preview
Go deeper on NCT07141199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07141199.